Navigation Links
BMC awarded NIH grant to train Ugandans in basic research on TB
Date:6/16/2014

(Boston)--Boston Medical Center (BMC) was recently awarded a five-year, $861,000 grant from the National Institutes of Health's Fogarty International Center to train Ugandans in basic research involving tuberculosis and emerging infectious diseases at Boston University School of Medicine. The award was funded by Fogarty's Global Infectious Disease (GID) Research Training program, and seeks to build research capacity related to infectious diseases that are endemic in developing countries. BMC was one of five institutions to receive funding to enhance infectious disease research training in low- and middle-income countries.

This grant will help to establish an important capacity-building initiative with Makerere University (MU) in Uganda that offers translational research training on immunology, inflammation, pathogenesis, bioinformatics on tuberculosis, emerging viral pathogens and antimicrobial resistance. The initiative will enable five postdoctoral faculty members from Makerere to obtain masters of art's degree in pathology at Boston University School of Medicine (BUSM) that includes two years of basic research training at the school.

The program will provide rigorous training in basic research approaches and methodology comparable to that of U.S. trainees. Once trained in a scientific discipline, the Ugandan trainee may choose a disease focus (TB or other emerging infectious diseases) or remain basic in orientation (immunology, bioinformatics) depending on their interest and the needs of MU.

"The goal of this program is to develop institutional and national capacity at MU to conduct basic sciences research on emerging infectious diseases and TB," explained Jerrold Ellner, MD, professor of infectious diseases at BUSM and Chief of infectious diseases at BMC and principal investigator of the award. Ellner has studied the immunopathogenesis of TB and TB in HIV patients through prior research collaborations in Uganda.

According to Ellner over the last two decades, MU has evolved into one of the principal academic institutions worldwide for collaborative research on TB and emerging infectious diseases. "Although donors have contributed substantial support for clinical research/training, we address an unmet need: training of future faculty in basic sciences research. The program will advance MU to a full self-sufficient partner and leader in diagnostics, treatments, vaccines and understanding the pathogenesis and correlates of protective immunity," he added.

The principal investigator in Uganda is Mose Joloba, MbChB, PhD, chair of the department of microbiology at MU. The scientific director is Caroline Genco, PhD, a professor of medicine, microbiology and immunology at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. JAX cancer researchers awarded NCI provocative questions grants
2. CHORI scientist Dan Granoff awarded prestigious Maurice Hillman/Merck Award
3. Beaumont Childrens Hospital awarded $20,000 from CureSearch for cancer research
4. UTMB awarded $4.4M to develop universal flu vaccine
5. Scientists awarded grant to develop diagnostics for cancer, rheumatoid arthritis, colitis
6. Dartmouth awarded lead role in NCI clinical trials network
7. LSUHSC awarded NSF grant for summer research experience for underrepresented undergrads
8. Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
9. LSTM-Eisai-UoL awarded GHIT Fund to deliver anti-Wolbachia drug discovery
10. Kessler Foundation MS scientist awarded Patterson Trust Award in Clinical Research
11. Sloan Research Fellowships awarded to 126 young scholars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Plastic Surgery, is excited to announce the arrival of the newest Sciton laser ... with the ability to use tunable non-ablative and ablative wavelengths for exceptional results. ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... 05, 2016 , ... Worldwise ®, a leading consumer ... kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise CEO. ... agreement three years ago to design and develop the kathy ireland® Loved Ones™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology: